Abacavir|P|ethanol|abacavir|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
Abacavir|P|methadone|ziagen|In a study of 11 HIV-infected patients receiving methadone-maintenance therapy -LRB- 40 mg and 90 mg daily -RRB- with 600 mg of ZIAGEN twice daily -LRB- twice the currently recommended dose -RRB- , oral methadone clearance increased 22 % -LRB- 90 % CI 6 % to 42 %-RRB-. 
Ezetimibe|P|cholestyramine|ezetimibe|Cholestyramine : Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55 %. 
Ezetimibe|P|ezetimibe|cholestyramine|The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction . 
Ezetimibe|P|zetia|fibrate|Co-administration of ZETIA with fibrates is not recommended until use in patients is studied . 
Ezetimibe|P|fenofibrate|ezetimibe|Fenofibrate : In a pharmacokinetic study , concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold . 
Ezetimibe|P|ezetimibe|cyclosporine|Cyclosporine : The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine . 
Ezetimibe|P|ezetimibe|cyclosporine|Patients who take both ezetimibe and cyclosporine should be carefully monitored . 
Fluconazole|P|diflucan|hypoglycemic agent|These are described in greater detail below : Oral hypoglycemics , Coumarin-type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short-acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
Fluconazole|P|diflucan|glyburide|one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use . 
Fluconazole|P|diflucan|tolbutamide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|P|diflucan|glyburide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|P|diflucan|glipizide|DIFLUCAN reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents . 
Fluconazole|P|diflucan|sulfonylurea oral hypoglycemic agent|When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary . 
Fluconazole|P|diflucan|coumarin-type anticoagulant|Coumarin-type anticoagulants : Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants . 
Fluconazole|P|fluconazole|warfarin|In post-marketing experience , as with other azole antifungals , bleeding events -LRB- bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena -RRB- have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin . 
Fluconazole|P|diflucan|coumarin-type anticoagulant|Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended . 
Fluconazole|P|diflucan|phenytoin|Phenytoin : DIFLUCAN increases the plasma concentrations of phenytoin . 
Fluconazole|P|diflucan|phenytoin|Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended . 
Fluconazole|P|diflucan|cyclosporine|Cyclosporine : DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment . 
Fluconazole|P|diflucan|cyclosporine|Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine . 
Fluconazole|P|rifampin|diflucan|Rifampin : Rifampin enhances the metabolism of concurrently administered DIFLUCAN . 
Fluconazole|P|diflucan|rifampin|Depending on clinical circumstances , consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin . 
Fluconazole|P|diflucan|rifampin|Depending on clinical circumstances , consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin . 
Fluconazole|P|diflucan|theophylline|Theophylline : DIFLUCAN increases the serum concentrations of theophylline . 
Fluconazole|P|diflucan|theophylline|Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended . 
Fluconazole|P|azole antifungal|terfenadine|Terfenadine : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine , interaction studies have been performed . 
Fluconazole|P|diflucan|terfenadine|Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly . 
Fluconazole|P|fluconazole|terfenadine|The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated . 
Fluconazole|P|fluconazole|terfenadine|The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored . 
Fluconazole|P|fluconazole|cisapride|Cisapride : There have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and cisapride were coadministered . 
Fluconazole|P|fluconazole|cisapride|A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval . 
Fluconazole|P|fluconazole|cisapride|The combined use of fluconazole with cisapride is contraindicated . 
Fluconazole|P|fluconazole|astemizole|Astemizole : The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 
Fluconazole|P|fluconazole|rifabutin|Rifabutin : There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered . 
Fluconazole|P|rifabutin|fluconazole|Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored . 
Fluconazole|P|fluconazole|tacrolimu|Tacrolimus : There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered . 
Fluconazole|P|tacrolimu|fluconazole|Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored . 
Fluconazole|P|midazolam|fluconazole|Short-acting Benzodiazepines : Following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
Fluconazole|P|midazolam|fluconazole|This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously . 
Fluconazole|P|short-acting benzodiazepine|fluconazole|If short-acting benzodiazepines , which are metabolized by the cytochrome P450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored . 
Fluconazole|P|fluconazole|ethinyl estradiol|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|P|fluconazole|levonorgestrel|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
Fluconazole|P|fluconazole|ethinyl estradiol|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Fluconazole|P|fluconazole|levonorgestrel|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
Mazindol|P|mazindol|nardil|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|parnate|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|phenelzine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|marplan|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|tranylcypromine|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|maoi|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|isocarboxazid|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|mazindol|monoamine oxidase inhibitor|You cannot take mazindol if you have taken a monoamine oxidase inhibitor -LRB- MAOI -RRB- such as isocarboxazid -LRB- Marplan -RRB- , tranylcypromine -LRB- Parnate -RRB- , or phenelzine -LRB- Nardil -RRB- in the last 14 days . 
Mazindol|P|insulin|mazindol|Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol . 
Mazindol|P|mazindol|ismelin|Mazindol may reduce the effects of guanethidine -LRB- Ismelin-RRB-. 
Mazindol|P|mazindol|guanethidine|Mazindol may reduce the effects of guanethidine -LRB- Ismelin-RRB-. 
Mebendazole|P|cimetidine|mebendazole|Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole . 
Mecamylamine|P|sulfonamide|ganglion blocker|Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers . 
Mecamylamine|P|antibiotic|ganglion blocker|Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers . 
Mecamylamine|P|mecamylamine|alcohol|The action of Mecamylamine may be potentiated by anesthesia , other antihypertensive drugs and alcohol . 
Mecamylamine|P|mecamylamine|antihypertensive drug|The action of Mecamylamine may be potentiated by anesthesia , other antihypertensive drugs and alcohol . 
Medroxyprogesterone|P|aminoglutethimide|depo-subq provera 104|Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA . 
Megestrol|P|megestrol acetate|indinavir|A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters -LRB- ~36 % for Cmax and ~28 % for AUC -RRB- of indinavir . 
Megestrol|P|indinavir|megestrol acetate|Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate . 
Melatonin|P|melatonin|beta blocker|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|fluvoxamine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|aspirin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|nsaid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|fluoxetine|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|benzodiazepene|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|corticosteroid|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Melatonin|P|melatonin|progestin|Melatonin may interact with the following drugs : aspirin and other NSAIDs -LRB- may lower melatonin levels -RRB- , fluvoxamine -LRB- bioavailability of oral melatonin is increased with coadministration -RRB- , beta blockers -LRB- may decrease melatonin levels -RRB- , fluoxetine -LRB- reports of psychotic episodes when coadministered -RRB- , progestin -LRB- coadministration of melatonin with progestin can inhibit ovarian function in women -RRB- , benzodiazepenes and other sedating drugs -LRB- may result in additive sedation and an increased incidence of adverse effects -RRB- , and corticosteroids -LRB- coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids -RRB-. 
Meloxicam|P|nsaid|angiotensin-converting enzyme (ace) inhibitor|ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme -LRB- ACE -RRB- inhibitors . 
Meloxicam|P|nsaid|ace inhibitor|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors . 
Meloxicam|P|aspirin|meloxicam|Aspirin : Concomitant administration of aspirin -LRB- 1000 mg TID -RRB- to healthy volunteers tended to increase the AUC -LRB- 10 % -RRB- and Cmax -LRB- 24 % -RRB- of meloxicam . 
Meloxicam|P|meloxicam|aspirin|however , as with other NSAIDs , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects . 
Meloxicam|P|nsaid|aspirin|however , as with other NSAIDs , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects . 
Meloxicam|P|aspirin|mobic|Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications , compared to use of MOBIC alone . 
Meloxicam|P|cholestyramine|meloxicam|Cholestyramine : Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 %. 
Meloxicam|P|nsaid|thiazide diuretic|Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
Meloxicam|P|nsaid|furosemide|Furosemide : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
Meloxicam|P|furosemide|mobic|Nevertheless , during concomitant therapy with furosemide and MOBIC , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy . 
Meloxicam|P|nsaid|lithium|Lithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
Meloxicam|P|lithium|meloxicam|In a study conducted in healthy subjects , mean pre-dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
Meloxicam|P|lithium|mobic|Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn . 
Meloxicam|P|lithium|mobic|Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn . 
Meloxicam|P|mobic|warfarin|Warfarin : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding . 
Meloxicam|P|mobic|warfarin|Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 
Melphalan|P|nalidixic acid|melphalan|DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
Melphalan|P|melphalan|cyclosporin|Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease 
Mepenzolate|P|anticholinergic drug|tricyclic antidepressant|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|sympathomimetic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|nitrite|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|nitrate|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|quinidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|antiarrhythmic agents of class i|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|antipsychotic agent|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|antihistamine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|benzodiazepine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|phenothiazine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|narcotic analgesic|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|mao inhibitor|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|meperidine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic drug|amantadine|The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I -LRB- e.g. , quinidine -RRB- , antihistamines , antipsychotic agents -LRB- e.g. , phenothiazines -RRB- , benzodiazepines , MAO inhibitors , narcotic analgesics -LRB- e.g. , meperidine -RRB- , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
Mepenzolate|P|anticholinergic|antiglaucoma agent|Anticholinergics antagonize the effects of antiglaucoma agents . 
Mepenzolate|P|anticholinergic drug|corticosteroid|Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids . 
Mepenzolate|P|anticholinergic agent|digoxin|Anticholinergic agents may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of digoxin ; 
Mepenzolate|P|anticholinergic drug|metoclopramide|Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility , such as metoclopramide . 
Mepenzolate|P|antacid|anticholinergic agent|Because antacids may interfere with the absorption of anticholinergic agents , simultaneous use of these drugs should be avoided . 
Meperidine|P|meperidine|narcotic analgesic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|narcotic analgesic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|anesthetic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|phenothiazine|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|tranquilizer|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|sedative-hypnotic|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|barbiturate|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|tricyclic antidepressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|cns depressant|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Meperidine|P|meperidine|alcohol|Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE-HYPNOTICS -LRB- INCLUDING BARBITURATES -RRB- , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS -LRB- INCLUDING ALCOHOL -RRB-. 
Mephenytoin|P|anticonvulsant|mephenytoin|Some anticonvulsants may interact with Mephenytoin . 
Mephenytoin|P|mephenytoin|steroid medication|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|steroid medication|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|furosemide|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|theophylline|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|warfarin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|warfarin|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|anti-infective medicine|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mephenytoin|P|mephenytoin|anti-infective medicine|Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
Mequitazine|P|mequitazine|cns depressant|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|P|mequitazine|maoi|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|P|mequitazine|alcohol|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|P|mequitazine|antichlolinergic|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Mequitazine|P|mequitazine|tca|Mequitazine can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and alcohol . 
Meropenem|P|probenecid|meropenem|Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem . 
Meropenem|P|probenecid|meropenem|Therefore , the coadministration of probenecid with meropenem is not recommended . 
Meropenem|P|meropenem|valproic acid|There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels -LRB- therapeutic range considered to be 50 to 100 g/mL total valproate -RRB-. 
Metaraminol|P|digitali|sympathomimetic amine|ARAMINE should be used with caution in digitalized patients , since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias . 
Metaraminol|P|monoamine oxidase inhibitor|sympathomimetic amine|Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines . 
Metaraminol|P|tricyclic antidepressant|sympathomimetic amine|Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines . 
Metaxalone|P|skelaxin|alcohol|SKELAXIN may enhance the effects of alcohol , barbiturates and other CNS depressants . 
Metaxalone|P|skelaxin|barbiturate|SKELAXIN may enhance the effects of alcohol , barbiturates and other CNS depressants . 
Metaxalone|P|skelaxin|cns depressant|SKELAXIN may enhance the effects of alcohol , barbiturates and other CNS depressants . 
Methazolamide|P|aspirin|methazolamide|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 
Methazolamide|P|aspirin|carbonic anhydrase inhibitor|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors . 
Methimazole|P|anticoagulant|methimazole|Anticoagulants -LRB- oral -RRB- : The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole . 
Methotrimeprazine|P|levomepromazine|opioid|Dosages of concomitantly administered opioids should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side-effects of opioids . 
Methotrimeprazine|P|opioid|levomepromazine|Dosages of concomitantly administered opioids should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side-effects of opioids . 
Methotrimeprazine|P|levomepromazine|benzodiazepine|Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates . 
Methotrimeprazine|P|levomepromazine|barbiturate|Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates . 
Methotrimeprazine|P|levomepromazine|antiparkinsonian-agent|Exert particular caution in combining levomepromazine with other anticholinergic drugs -LRB- tricyclic antidepressants and antiparkinsonian-agents -RRB- : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
Methotrimeprazine|P|levomepromazine|tricyclic antidepressant|Exert particular caution in combining levomepromazine with other anticholinergic drugs -LRB- tricyclic antidepressants and antiparkinsonian-agents -RRB- : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
Methotrimeprazine|P|levomepromazine|anticholinergic drug|Exert particular caution in combining levomepromazine with other anticholinergic drugs -LRB- tricyclic antidepressants and antiparkinsonian-agents -RRB- : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
Methotrimeprazine|P|amphetamine|levomepromazine|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine . 
Methotrimeprazine|P|amphetamine|levomepromazine|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine . 
Methotrimeprazine|P|caffeine|levomepromazine|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine . 
Methsuximide|P|celontin|antiepileptic drug|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|P|methsuximide|antiepileptic drug|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|P|methsuximide|phenytoin|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methsuximide|P|methsuximide|phenobarbital|Since Celontin -LRB- methsuximide -RRB- may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary -LRB- eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital -RRB-. 
Methyclothiazide|P|thiazide|norepinephrine|Thiazides may decrease arterial responsiveness to norepinephrine . 
Methyclothiazide|P|thiazide drug|tubocurarine|Thiazide drugs may increase the responsiveness of tubocurarine . 
Methyclothiazide|P|lithium|thiazide|Lithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity . 
Methyclothiazide|P|thiazide|antihypertensive drug|Thiazides may add to or potentiate the action of other antihypertensive drugs . 
Methyldopa|P|methyldopa|antihypertensive drug|When methyldopa is used with other antihypertensive drugs , potentiation of antihypertensive effect may occur . 
Methyldopa|P|anesthetic|methyldopa|Patients may require reduced doses of anesthetics when on methyldopa . 
Methyldopa|P|methyldopa|lithium|When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity . 
Methyldopa|P|methyldopa|ferrous sulfate|Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . 
Methyldopa|P|methyldopa|ferrous gluconate|Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . 
Methyldopa|P|methyldopa|ferrous gluconate|Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended . 
Methyldopa|P|methyldopa|ferrous sulfate|Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended . 
Methylergonovine|P|methylergonovine maleate|vasoconstrictor|Caution should be exercised when Methergine -LRB- methylergonovine maleate -RRB- is used concurrently with other vasoconstrictors or ergot alkaloids . 
Methylergonovine|P|methergine|ergot alkaloid|Caution should be exercised when Methergine -LRB- methylergonovine maleate -RRB- is used concurrently with other vasoconstrictors or ergot alkaloids . 
Methylergonovine|P|methergine|vasoconstrictor|Caution should be exercised when Methergine -LRB- methylergonovine maleate -RRB- is used concurrently with other vasoconstrictors or ergot alkaloids . 
Methylphenidate|P|ritalin|guanethidine|Ritalin may decrease the hypotensive effect of guanethidine . 
Methylphenidate|P|ritalin|imipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|tricyclic drug|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|desipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|clomipramine|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|diphenylhydantoin|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|phenobarbital|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|phenylbutazone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|primidone|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|anticonvulsant|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylphenidate|P|ritalin|coumarin anticoagulant|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants -LRB- phenobarbital , diphenylhydantoin , primidone -RRB- , phenylbutazone , and tricyclic drugs -LRB- imipramine , clomipramine , desipramine -RRB-. 
Methylprednisolone|P|cyclosporin|methylprednisolone|Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone ; 
Methylprednisolone|P|methylprednisolone|cyclosporin|convulsions have been reported with concurrent use of methylprednisolone and cyclosporin . 
Methylprednisolone|P|phenytoin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenytoin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenytoin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenytoin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenytoin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenytoin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|rifampin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|rifampin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|rifampin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|rifampin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|rifampin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|rifampin|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenobarbital|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenobarbital|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenobarbital|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenobarbital|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenobarbital|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|phenobarbital|methylprednisolone|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
Methylprednisolone|P|ketoconazole|methylprednisolone|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance . 
Methylprednisolone|P|troleandomycin|methylprednisolone|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance . 
Methylprednisolone|P|methylprednisolone|aspirin|Methylprednisolone may increase the clearance of chronic high dose aspirin . 
Methylprednisolone|P|salicylate|methylprednisolone|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn . 
Methylprednisolone|P|aspirin|corticosteroid|Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia . 
Methylprednisolone|P|anticoagulant|corticosteroid|There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids . 
Methylscopolamine|P|methscopolamine|chlorpromazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|promethazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|isocarboxazid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|tranylcypromine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|furazolidone|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|selegiline|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|quinidine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|mao inhibitor|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|tricyclic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|linezolid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|phenelzine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|phenothiazine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|absorbent-type anti-diarrhea medicine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|kaolin|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|potassium chloride|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|antacid|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|anticholinergic|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|diphenhydramine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|antihistamine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methylscopolamine|P|methscopolamine|amantadine|Methscopolamine may interact with antidepressants -LRB- tricyclic type -RRB- , MAO inhibitors -LRB- e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone -RRB- , quinidine , amantadine , antihistamines -LRB- e.g. , diphenhydramine -RRB- , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines -LRB- e.g. , kaolin-pectin -RRB- , phenothiazines -LRB- e.g. , chlorpromazine , promethazine -RRB-. 
Methyprylon|P|cns depression-producing drug|methyprylon|Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications . 
Methyprylon|P|alcohol|methyprylon|Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications . 
Methysergide|P|methysergide|narcotic analgesic|Methysergide may reverse the analgesic activity of narcotic analgesics . 
Metoclopramide|P|metoclopramide|narcotic analgesic|The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics . 
Metoclopramide|P|metoclopramide|anticholinergic drug|The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics . 
Metoclopramide|P|metoclopramide|narcotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|P|metoclopramide|tranquilizer|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|P|metoclopramide|sedative|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|P|metoclopramide|hypnotic|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|P|metoclopramide|alcohol|Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers . 
Metoclopramide|P|metoclopramide|monoamine oxi-dase inhibitor|The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving monoamine oxi-dase inhibitors . 
Metoclopramide|P|digoxin|metoclopramide|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|P|metoclopramide|acetaminophen|Absorption of drugs from the stomach may be diminished -LRB- e.g. , digoxin -RRB- by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased -LRB- e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine -RRB-. 
Metoclopramide|P|metoclopramide|insulin|Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption , insulin dosage or timing of dosage may require adjustment . 
Metolazone|P|furosemide|metolazone|Diuretics : Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
Metolazone|P|loop diuretic|metolazone|Diuretics : Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
Metolazone|P|mykrox|antihypertensive drug|Other Antihypertensives : When MYKROX Tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy . 
Metolazone|P|diuretic|digitali|Digitalis Glycosides : Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis . 
Metolazone|P|diuretic|tubocurarine|Curariform Drugs : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs -LRB- such as tubocurarine -RRB- the most serious effect would be respiratory depression which could proceed to apnea . 
Metolazone|P|diuretic|curariform drug|Curariform Drugs : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs -LRB- such as tubocurarine -RRB- the most serious effect would be respiratory depression which could proceed to apnea . 
Metolazone|P|non-steroidal anti-inflammatory drug|mykrox|Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs : May decrease the antihypertensive effects of MYKROX Tablets . 
Metolazone|P|salicylate|mykrox|Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs : May decrease the antihypertensive effects of MYKROX Tablets . 
Metolazone|P|metolazone|norepinephrine|Sympathomimetics : Metolazone may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 
Metolazone|P|methenamine|metolazone|Methenamine : Efficacy may be decreased due to urinary alkalizing effect of metolazone . 
Metolazone|P|metolazone|anticoagulant|Anticoagulants : Metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
Metoprolol|P|reserpine|beta-blocking agent|Catecholamine-depleting drugs -LRB- e.g. , reserpine -RRB- may have an additive effect when given with beta-blocking agents . 
Metronidazole|P|metronidazole|coumarin|Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time . 
Metronidazole|P|metronidazole|warfarin|Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time . 
Metyrapone|P|metopirone|phenytoin|The metabolism of Metopirone is accelerated by phenytoin ; 
Metyrapone|P|metopirone|acetaminophen|Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity . 
Metyrapone|P|metopirone|acetaminophen|Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity . 
Metyrosine|P|demser|haloperidol|Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 
Metyrosine|P|demser|phenothiazine|Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 
Metyrosine|P|demser|cns depressant|Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects . 
Metyrosine|P|demser|alcohol|Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects . 
Mexiletine|P|mexiletine|fluvoxamine|In a formal , single-dose interaction study -LRB- n = 6 males -RRB- the clearance of mexiletine was decreased by 38 % following the coadministration of fluvoxamine , an inhibitor of CYP1A2 . 
Mexiletine|P|phenobarbital|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|P|phenytoin|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|P|rifampin|mexitil|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
Mexiletine|P|cimetidine|mexitil|Concurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; 
Mexiletine|P|magnesium-aluminum hydroxide|digoxin|Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
Mexiletine|P|mexitil|theophylline|Concurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . 
Mexiletine|P|mexitil|theophylline|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|P|theophylline|mexitil|This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
Mexiletine|P|caffeine|mexitil|Additionally , in one controlled study in five normal subjects and seven patients , the clearance of caffeine was decreased 50 % following the administration of Mexitil . 
Mibefradil|P|posicor|cyclosporine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|P|posicor|tricyclic antidepressant|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|P|posicor|astemizole|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|P|posicor|cisapride|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Mibefradil|P|posicor|terfenadine|Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
Micafungin|P|sirolimu|mycamine|Sirolimus AUC was increased by 21 % with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone . 
Micafungin|P|nifedipine|mycamine|Nifedipine AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state MYCAMINE compared with nifedipine alone . 
Micafungin|P|nifedipine|mycamine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Micafungin|P|sirolimu|mycamine|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
Midazolam|P|midazolam|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|macrolide antibiotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|protease inhibitor|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|protease inhibitor|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|calcium channel antagonist|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|calcium channel antagonist|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|azole antimycotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|midazolam|azole antimycotic|Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system -LRB- ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics -RRB-. 
Midazolam|P|fluconazole|midazolam|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|P|ketoconazole|midazolam|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|P|itraconazole|midazolam|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|P|verapamil|midazolam|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|P|diltiazem|midazolam|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|P|erythromycin|midazolam|Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
Midazolam|P|ritonavir|midazolam|Although not studied , the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam . 
Midazolam|P|nelfinavir|midazolam|Although not studied , the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam . 
Midazolam|P|carbamazepine|midazolam|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|P|rifampin|midazolam|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|P|phenytoin|midazolam|Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
Midazolam|P|versed syrup|propofol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|propofol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|ketamine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|nitrous oxide|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|secobarbital|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|droperidol|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|morphine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|morphine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|narcotic|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|narcotic|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|fentanyl|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|meperidine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midazolam|P|versed syrup|meperidine|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics -LRB- eg , morphine , meperidine and fentanyl -RRB- , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
Midodrine|P|proamatine|cardiac glycoside|When administered concomitantly with ProAmatine , cardiac glycosides may enhance or precipitate bradycardia , A.V. . 
Midodrine|P|ephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|ephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|pseudoephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|pseudoephedrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|phenylephrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|phenylephrine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|phenylpropanolamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|phenylpropanolamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|dihydroergotamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|dihydroergotamine|proamatine|The use of drugs that stimulate alpha-adrenergic receptors -LRB- e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine -RRB- may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
Midodrine|P|desglymidodrine|quinidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|desglymidodrine|flecainide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|desglymidodrine|triamterene|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|desglymidodrine|ranitidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|desglymidodrine|procainamide|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|terazosin|proamatine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|desglymidodrine|metformin|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|desglymidodrine|cimetidine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|prazosin|proamatine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|doxazosin|proamatine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Midodrine|P|alpha-adrenergic blocking agent|proamatine|ProAmatine. Alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine -LRB- a base -RRB- is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
Mifepristone|P|itraconazole|mifepristone|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|P|erythromycin|mifepristone|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|P|ketoconazole|mifepristone|Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism -LRB- increasing serum levels of mifepristone -RRB-. 
Mifepristone|P|phenytoin|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|P|anticonvulsant|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|P|phenobarbital|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Mifepristone|P|carbamazepine|mifepristone|John s Wort , and certain anticonvulsants -LRB- phenytoin , phenobarbital , carbamazepine -RRB- may induce mifepristone metabolism -LRB- lowering serum levels of mifepristone -RRB-. 
Miglustat|P|zavesca|cerezyme|While co-administration of ZAVESCA appeared to increase the clearance of Cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . 
Miglustat|P|imiglucerase|zavesca|Combination therapy with Cerezyme -LRB- imiglucerase -RRB- and ZAVESCA is not indicated . 
Miglustat|P|cerezyme|zavesca|Combination therapy with Cerezyme -LRB- imiglucerase -RRB- and ZAVESCA is not indicated . 
Minocycline|P|tetracycline|anticoagulant|Because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage . 
Minocycline|P|tetracycline|anticoagulant|Because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage . 
Minocycline|P|tetracycline class drug|penicillin|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin . 
Minocycline|P|tetracycline|aluminum|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|P|tetracycline|magnesium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|P|tetracycline|magnesium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|P|tetracycline|calcium|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|P|tetracycline|iron|Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations . 
Minocycline|P|tetracycline|methoxyflurane|The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity . 
Minocycline|P|tetracycline|contraceptive|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective . 
Minoxidil|P|minoxidil|guanethidine|Interaction with Guanethidine : Although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . 
Minoxidil|P|guanethidine|minoxidil|If at all possible guanethidine should be discontinued well before minoxidil is begun . 
Mirtazapine|P|alcohol|mirtazapine|Alcohol : Concomitant administration of alcohol -LRB- equivalent to 60 g -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 6 healthy male subjects . 
Mirtazapine|P|remeron|alcohol|However , the impairment of cognitive and motor skills produced by REMERON were shown to be additive with those produced by alcohol . 
Mirtazapine|P|diazepam|mirtazapine|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|P|alcohol|remeron soltab|Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam -LRB- 15 mg -RRB- had a minimal effect on plasma levels of mirtazapine -LRB- 15 mg -RRB- in 12 healthy subjects . 
Mirtazapine|P|remeron|diazepam|However , the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam . 
Mirtazapine|P|diazepam|remeron soltab|Accordingly , patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab . 
Mitotane|P|mitotane|warfarin|Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin . 
Mitotane|P|mitotane|coumarin-type anticoagulant|Therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants . 
Mivacurium|P|succinylcholine|nondepolarizing agent|Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents . 
Mivacurium|P|succinylcholine|mivacron|Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON . 
Mivacurium|P|mivacron|aminoglycoside|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|aminoglycoside|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|tetracycline|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|tetracycline|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|antibiotic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|antibiotic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|lithium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|anesthetic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|procainamide|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|quinidine|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|clindamycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|colistin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|lincomycin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|sodium colistimethate|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|polymyxin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|magnesium|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|tetracycline|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|tetracycline|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|bacitracin|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|antibiotic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|antibiotic|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|aminoglycoside|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|nondepolarizing agent|aminoglycoside|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics -LRB- e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate -RRB- , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
Mivacurium|P|mivacron|glucocorticoid|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|mivacron|glucocorticoid|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|mivacron|contraceptive|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|mivacron|contraceptive|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|mivacron|monoamine oxidase inhibitor|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|mivacron|monoamine oxidase inhibitor|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|neuromuscular blocking agent|carbamazepine|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|neuromuscular blocking agent|phenytoin|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity -LRB- e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors -RRB- or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
Mivacurium|P|carbamazepine|mivacron|While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 
Mivacurium|P|phenytoin|mivacron|While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 
Moexipril|P|spironolactone|ace inhibitor|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|P|potassium-sparing diuretic|ace inhibitor|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|P|triamterene|ace inhibitor|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|P|potassium|ace inhibitor|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|P|amiloride|ace inhibitor|Use of potassium-sparing diuretics -LRB- spironolactone , triamterene , amiloride -RRB- or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
Moexipril|P|ace inhibitor|lithium|Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
Moexipril|P|diuretic|lithium|If a diuretic is also used , the risk of lithium toxicity may be increased . 
Mometasone|P|ketoconazole|mometasone furoate|However , ketoconazole , a potent inhibitor of cytochrome P450 3A4 , may increase plasma levels of mometasone furoate during concomitant dosing . 
Montelukast|P|rifampin|montelukast|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast . 
Montelukast|P|phenobarbital|montelukast|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast . 
Montelukast|P|rifampin|montelukast|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast . 
Montelukast|P|phenobarbital|montelukast|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast . 
Morphine|P|morphine|psychotropic drug|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|P|morphine|cns depressant|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|P|morphine|sedative|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|P|morphine|alcohol|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|P|morphine|antihistaminic|Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
Morphine|P|neuroleptic|morphine|Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression , hypotension and profound sedation or coma . 
Morphine|P|agonist/antagonist analgesic|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|agonist/antagonist analgesic|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|buprenorphine|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|buprenorphine|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|pentazocine|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|pentazocine|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|nalbuphine|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|nalbuphine|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|butorphanol|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Morphine|P|butorphanol|opioid agonist analgesic|Interaction with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics -LRB- i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine -RRB- should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
Mycophenolic acid|P|myfortic|magnesium|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|P|myfortic|magnesium|Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids -LRB- 30 mL -RRB- : the mean Cmax and AUC -LRB- 0-t -RRB- values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
Mycophenolic acid|P|myfortic|antacid|It is recommended that Myfortic and antacids not be administered simultaneously . 
Mycophenolic acid|P|myfortic|azathioprine|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|P|myfortic|mycophenolate mofetil|Azathioprine/Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
Mycophenolic acid|P|myfortic|cholestyramine|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|P|myfortic|activated charcoal|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|P|myfortic|activated charcoal|Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
Mycophenolic acid|P|levonorgesterol|mycophenolate mofetil|However , in a drug-drug interaction study , mean levonorgesterol AUC was decreased by 15 % when coadministered with mycophenolate mofetil . 
Mycophenolic acid|P|contraceptive|myfortic|Therefore , it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered . 
Mycophenolic acid|P|myfortic|live attenuated vaccine|Live Vaccines : During treatment with Myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . 
Ondansetron|P|carbamazepine|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|P|rifampicin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|P|rifampicin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|P|phenytoin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|P|phenytoin|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|P|carbamazepine|ondansetron|Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 -LRB- i.e. , phenytoin , carbamazepine , and rifampicin -RRB- , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
Ondansetron|P|ondansetron|tramadol|However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
Orciprenaline|P|beta adrenergic aerosol bronchodilator|alupent|Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent -LRB- metaproterenol sulfate USP -RRB- because they may have additive effects . 
Orciprenaline|P|beta adrenergic aerosol bronchodilator|metaproterenol sulfate|Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent -LRB- metaproterenol sulfate USP -RRB- because they may have additive effects . 
Orciprenaline|P|beta adrenergic agonist|monoamine oxidase inhibitor|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
Orciprenaline|P|beta adrenergic agonist|tricyclic antidepressant|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
Orlistat|P|xenical|cyclosporine|Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
Orlistat|P|beta-carotene|xenical|Fat-soluble Vitamin Supplements and Analogues : A pharmacokinetic interaction study showed a 30 % reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL . 
Orlistat|P|xenical|vitamin e acetate|XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60 %. 
Orlistat|P|vitamin k|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|P|warfarin|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Orlistat|P|warfarin|xenical|Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
Oxacillin|P|tetracycline|penicillin|Tetracycline , a bacteriostatic antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided . 
Oxaliplatin|P|5-fu|eloxatin|Increases of 5-FU plasma concentrations by approximately 20 % have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks . 
Oxandrolone|P|anabolic steroid|anticoagulant|Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants . 
Oxandrolone|P|oxandrolone|warfarin|Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr/mL : similar increases in R-warfarin half-life and AUC were also detected . 
Oxandrolone|P|oxandrolone|warfarin|When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin , the INR or prothrombin time -LRB- PT -RRB- should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved . 
Oxandrolone|P|warfarin|oxandrolone|Furthermore , in patients receiving both drugs , careful monitoring of the INR or PT , and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued . 
Oxandrolone|P|warfarin|oxandrolone|Furthermore , in patients receiving both drugs , careful monitoring of the INR or PT , and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued . 
Oxandrolone|P|oxandrolone|hypoglycemic agent|Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents . 
Oxybutynin|P|oxybutynin|anticholinergic drug|The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth , constipation , somnolence -LRB- drowsiness -RRB- , and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects . 
Oxybutynin|P|ditropan xl|ketoconazole|Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole , a potent CYP3A4 inhibitor . 
Oxybutynin|P|erythromycin|oxybutynin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|P|macrolide antibiotic|oxybutynin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|P|miconazole|oxybutynin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|P|antimycotic agent|oxybutynin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|P|clarithromycin|oxybutynin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxybutynin|P|itraconazole|oxybutynin|Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents -LRB- e.g. , itraconazole and miconazole -RRB- or macrolide antibiotics -LRB- e.g. , erythromycin and clarithromycin -RRB- , may alter oxybutynin mean pharmacokinetic parameters -LRB- i.e. , Cmax and AUC -RRB-. 
Oxycodone|P|oxycodone hydrochloride|cns depressant|The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants .. 
Oxymorphone|P|anticholinergic|opioid analgesic|Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation , which may lead to paralytic ileus . 
Oxymorphone|P|oxymorphone|propofol|It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia . 
Oxymorphone|P|cimetidine|opioid analgesic|In addition , CNS toxicity has been reported -LRB- confusion , disorientation , respiratory depression , apnea , seizures -RRB- following coadministration of cimetidine with opioid analgesics ; 
Paliperidone|P|paliperidone|centrally acting drug|Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . 
Paliperidone|P|invega|alcohol|Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . 
Paliperidone|P|invega|centrally acting drug|Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . 
Paliperidone|P|paliperidone|alcohol|Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . 
Paliperidone|P|paliperidone|dopamine agonist|Paliperidone may antagonize the effect of levodopa and other dopamine agonists . 
Paliperidone|P|paliperidone|levodopa|Paliperidone may antagonize the effect of levodopa and other dopamine agonists . 
Pantoprazole|P|pantoprazole|warfarin|There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly . 
Pantoprazole|P|proton pump inhibitor|warfarin|There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly . 
Pantoprazole|P|proton pump inhibitor|warfarin|Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time . 
Pantoprazole|P|pantoprazole|ketoconazole|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|P|pantoprazole|iron|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Pantoprazole|P|pantoprazole|ampicillin|Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability -LRB- eg , ketoconazole , ampicillin esters , and iron salts -RRB-. 
Paricalcitol|P|paricalcitol|nelfinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|ritonavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|saquinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|telithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|voriconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|atazanavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|ketoconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|indinavir|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|ketoconazole|paricalcitol|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|clarithromycin|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|nefazodone|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|paricalcitol|itraconazole|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
Paricalcitol|P|zemplar|ketoconazole|Dose adjustment of Zemplar Capsules may be required , and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole . 
Paricalcitol|P|fat-soluble vitamin|cholestyramine|Drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of Zemplar Capsules . 
Paricalcitol|P|fat-soluble vitamin|cholestyramine|Drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of Zemplar Capsules . 
Paricalcitol|P|cholestyramine|zemplar|Drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of Zemplar Capsules . 
Pegfilgrastim|P|lithium|neulasta|patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts . 
Peginterferon alfa-2b|P|methadone|peg-intron|In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone , treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16 % in methadone AUC ; 
Pegvisomant|P|hypoglycemic|somavert|Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT . 
Pegvisomant|P|insulin|somavert|Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT . 
Pegvisomant|P|opioid|pegvisomant|In clinical studies , patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids . 
Pemetrexed|P|probenecid|alimta|Concomitant administration of substances that are also tubularly secreted -LRB- e.g. , probenecid -RRB- could potentially result in delayed clearance of ALIMTA . 
Pemetrexed|P|ibuprofen|alimta|Although ibuprofen -LRB- 400 mg qid -RRB- can be administered with ALIMTA in patients with normal renal function -LRB- creatinine clearance 80 mL/min -RRB- , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency -LRB- creatinine clearance from 45 to 79 mL/min -RRB-. 
Pemetrexed|P|nsaid|alimta|Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before , the day of , and 2 days following administration of ALIMTA . 
Pemetrexed|P|nsaid|alimta|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
Pemoline|P|cylert|antiepileptic medication|Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications . 
Penicillin G|P|bacteriostatic antibiotic|penicillin|Concurrent administration of bacteriostatic antibiotics -LRB- e.g. , erythromycin , tetracycline -RRB- may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
Penicillin G|P|erythromycin|penicillin|Concurrent administration of bacteriostatic antibiotics -LRB- e.g. , erythromycin , tetracycline -RRB- may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
Penicillin G|P|tetracycline|penicillin|Concurrent administration of bacteriostatic antibiotics -LRB- e.g. , erythromycin , tetracycline -RRB- may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
Penicillin G|P|penicillin|probenecid|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins . 
Pentazocine|P|alcohol|pentazocine|Usage with Alcohol : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine . 
Pentazocine|P|alcohol|pentazocine|Usage with Alcohol : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine . 
Pentoxifylline|P|trental|platelet aggregation inhibitor|Although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors . 
Pentoxifylline|P|trental|anticoagulant|Although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors . 
Pentoxifylline|P|trental|theophylline|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
Pergolide|P|neuroleptic|permax|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|P|phenothiazine|permax|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|P|thioxanthine|permax|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|P|butyrophenone|permax|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|P|metoclopramide|permax|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Pergolide|P|dopamine antagonist|permax|Dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthines -RRB- or metoclopramide , ordinarily should not be administered concurrently with Permax -LRB- a dopamine agonist -RRB-; 
Perindopril|P|diuretic|aceon|Diuretics : Patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of ACEON Tablets therapy . 
Perindopril|P|diuretic|perindopril|The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril . 
Perindopril|P|diuretic|aceon|If diuretics cannot be interrupted , close medical supervision should be provided with the first dose of ACEON Tablets , for at least two hours and until blood pressure has stabilized for another hour . 
Perindopril|P|digoxin|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|P|digoxin|perindopril|Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded . 
Perindopril|P|perindopril|gentamicin|Gentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . 
Phentermine|P|alcohol|phentermine hydrochloride|Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction . 
Phenylephrine|P|vasopressor|halothane|Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
Phenylephrine|P|metaraminol|halothane|Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
Phenylephrine|P|sympathomimetic pressor amine|maoi|MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylephrine|P|sympathomimetic pressor amine|monoamine oxidase inhibitor|MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylephrine|P|adrenergic agent|tricyclic antidepressant|The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants . 
Phenylpropanolamine|P|vasopressor|halothane|Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
Phenylpropanolamine|P|metaraminol|halothane|Vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
Phenylpropanolamine|P|sympathomimetic pressor amine|monoamine oxidase inhibitor|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylpropanolamine|P|sympathomimetic pressor amine|maoi|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors -LRB- MAOI-RRB-. 
Phenylpropanolamine|P|adrenergic agent|tricyclic antidepressant|The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants . 
Pilocarpine|P|pilocarpine|beta adrenergic antagonist|Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances . 
Pindolol|P|reserpine|beta-blocking agent|Catecholamine-depleting drugs -LRB- e.g. , reserpine -RRB- may have an additive effect when given with beta-blocking agents . 
Pindolol|P|pindolol|thioridazine|Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered . 
Pirbuterol|P|short-acting beta adrenergic aerosol bronchodilator|maxair autohaler|Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects . 
Piroxicam|P|feldene|coumarin-type anticoagulant|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|P|coumarin-type anticoagulant|feldene|Although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs . 
Piroxicam|P|nonsteroidal anti-inflammatory agent|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|P|feldene|lithium|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|P|feldene|aspirin|Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin -LRB- 3900 mg/day -RRB- , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
Piroxicam|P|lithium|feldene|It is recommended that plasma lithium levels be monitored when initiating , adjusting and discontinuing FELDENE . 
Pralidoxime|P|atropine|pralidoxime|When atropine and pralidoxime are used together , the signs of atropinization -LRB- flushing , mydriasis , tachycardia , dryness of the mouth and nose -RRB- may occur earlier than might be expected when atropine is used alone . 
Pralidoxime|P|barbiturate|anticholinesterase|2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ; 
Pramipexole|P|cimetidine|pramipexole|Cimetidine : Cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole AUC and a 40 % increase in half-life -LRB- N= 12 -RRB-. 
Pramipexole|P|quinine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|quinine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|diltiazem|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|diltiazem|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|cimetidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|cimetidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|quinidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|quinidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|ranitidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|ranitidine|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|chlorpropamide|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|verapamil|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|verapamil|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|cephalosporin|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|indomethacin|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|hydrochlorothiazide|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|penicillin|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|triamterene|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|triamterene|pramipexole|Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system -LRB- e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine -RRB- decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system -LRB- e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide -RRB- are likely to have little effect on the oral clearance of pramipexole . 
Pramipexole|P|dopamine antagonist|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|P|thioxanthene|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|P|metoclopramide|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|P|butyrophenone|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|P|phenothiazine|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramipexole|P|neuroleptic|mirapex|Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics -LRB- phenothiazines , butyrophenones , thioxanthenes -RRB- or metoclopramide , may diminish the effectiveness of MIRAPEX . 
Pramlintide|P|symlin|alpha glucosidase inhibitor|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|P|symlin|alpha glucosidase inhibitor|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|P|symlin|anticholinergic agent|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|P|symlin|atropine|Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility -LRB- e.g. , anticholinergic agents such as atropine -RRB- and agents that slow the intestinal absorption of nutrients -LRB- e.g. , alpha glucosidase inhibitors -RRB-. 
Pramlintide|P|analgesic|symlin|When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness -LRB- such as analgesics -RRB- , the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection . 
Pramlintide|P|symlin|human insulin|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection . 
Prednisone|P|rifampin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|rifampin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenobarbital|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenobarbital|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenobarbital|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenobarbital|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenytoin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenytoin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenytoin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|phenytoin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|rifampin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|rifampin|corticosteroid|Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
Prednisone|P|ketoconazole|corticosteroid|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance . 
Prednisone|P|troleandomycin|corticosteroid|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance . 
Prednisone|P|corticosteroid|aspirin|Corticosteroids may increase the clearance of chronic high dose aspirin . 
Prednisone|P|salicylate|corticosteroid|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn . 
Prednisone|P|aspirin|corticosteroid|Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia . 
Prednisone|P|corticosteroid|anticoagulant|The effect of corticosteroids on oral anticoagulants is variable . 
Prednisone|P|anticoagulant|corticosteroid|There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids . 
Procaine|P|anticholinesterase|procaine hydrochloride|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|P|procaine hydrochloride|anticholinesterase agent|Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
Procaine|P|procaine hydrochloride|cns depressant medication|CNS depressant medications : Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects . 
Procaine|P|hyaluronidase|procaine hydrochloride|Hyaluronidase : Hyaluronidase may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity . 
Procaine|P|procaine hydrochloride|neuromuscular blocking agent|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|P|procaine hydrochloride|neuromuscular blocking agent|Neuromuscular blocking agents -LRB- such as suxamethonium chloride -RRB- : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
Procaine|P|procaine hydrochloride|sulfonamide|Sulfonamides : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
Procaine|P|acetazolamide|procaine hydrochloride|Acetazolamide : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine . 
Procarbazine|P|matulane|tyramine|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|P|matulane|amitriptyline hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|P|matulane|imipramine hcl|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|P|matulane|sympathomimetic drug|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Procarbazine|P|matulane|tricyclic antidepressant|Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs -LRB- e.g. , amitriptyline HCl , imipramine HCl -RRB- and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
Prochlorperazine|P|thiazide diuretic|phenothiazine|Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines . 
Prochlorperazine|P|thiazide diuretic|phenothiazine|Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines . 
Prochlorperazine|P|guanethidine|phenothiazine|Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly . 
Prochlorperazine|P|propranolol|phenothiazine|Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs . 
Propofol|P|diprivan|morphine|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|P|diprivan|meperidine|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|P|diprivan|narcotic|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|P|diprivan|fentanyl|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics -LRB- eg , morphine , meperidine , and fentanyl , etc .-RRB- 
Propofol|P|diprivan|opioid|During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents -LRB- eg , nitrous oxide or opioids -RRB-. 
Propofol|P|diprivan|analgesic agent|During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents -LRB- eg , nitrous oxide or opioids -RRB-. 
Propofol|P|diprivan|nitrous oxide|During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents -LRB- eg , nitrous oxide or opioids -RRB-. 
Propoxyphene|P|propoxyphene|cns depressant|The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants , including alcohol . 
Propoxyphene|P|propoxyphene|alcohol|The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants , including alcohol . 
Pseudoephedrine|P|beta adrenergic blocker|pseudoephedrine|MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . 
Pseudoephedrine|P|mao inhibitor|pseudoephedrine|MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . 
Pseudoephedrine|P|sympathomimetic|reserpine|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|P|sympathomimetic|veratrum alkaloid|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|P|sympathomimetic|methyldopa|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pseudoephedrine|P|sympathomimetic|mecamylamine|Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids . 
Pyrimethamine|P|lorazepam|pyrimethamine|Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly . 
Raloxifene|P|cholestyramine|raloxifene|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|P|cholestyramine|evista|Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
Raloxifene|P|evista|warfarin|If EVISTA is given concurrently with warfarin , prothrombin time should be monitored . 
Raloxifene|P|evista|ibuprofen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|P|evista|diazepam|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|P|evista|diazoxide|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|P|evista|clofibrate|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|P|evista|indomethacin|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Raloxifene|P|evista|naproxen|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
Ranitidine|P|tritec|clarithromycin|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations -LRB- 57 % -RRB- , increased plasma bismuth trough concentrations -LRB- 48 % -RRB- , and increased 14- hydroxy- clarithromycin plasma concentrations -LRB- 31%-RRB-. 
Ranitidine|P|antacid|ranitidine|Coadministration with a high dose of antacid -LRB- 170 mEq -RRB- results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC . 
Ranitidine|P|antacid|tritec|Coadministration with a high dose of antacid -LRB- 170 mEq -RRB- results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC . 
Retapamulin|P|ketoconazole|retapamulin|Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC -LRB- 0-24 -RRB- and Cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males . 
Reteplase|P|vitamin k antagonist|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|heparin|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|dipyridamole|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|dipyridamole|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|abciximab|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|abciximab|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|aspirin|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Reteplase|P|aspirin|retavase|In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function -LRB- such as aspirin , dipyridamole , and abciximab -RRB- may increase the risk of bleeding if administered prior to or after Retavase therapy . 
Riboflavin|P|alcohol|riboflavin|Interactions for Vitamin B2 -LRB- Riboflavin -RRB- : Alcohol - impairs the intestinal absorption of riboflavin 
Riboflavin|P|probenecid|riboflavin|Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin ; 
Riboflavin|P|riboflavin|probenecid|requirements for riboflavin may be increased in patients receiving probenecid . 
Rimantadine|P|rimantadine hcl|cimetidine|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine -LRB- 300 mg four times a day -RRB- , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % -LRB- compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine -RRB-. 
Rimantadine|P|acetaminophen|rimantadine|Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11 %. 
Rimantadine|P|rimantadine|aspirin|Peak plasma concentrations and AUC of rimantadine were reduced approximately 10 % in the presence of aspirin . 
Rivastigmine|P|cholinesterase inhibitor|anticholinergic medication|Use with Anticholinergics : Because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications . 
Rivastigmine|P|cholinesterase inhibitor|neuromuscular blocking agent|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|P|cholinesterase inhibitor|succinylcholine|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|P|cholinesterase inhibitor|bethanechol|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rivastigmine|P|cholinesterase inhibitor|cholinergic agonist|Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
Rocuronium|P|zemuron|succinylcholine|If ZEMURON is administered following administration of succinylcholine , it should not be given until recovery from succinylcholine has been observed . 
Ropivacaine|P|ropivacaine|anesthetic|Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive . 
Ropivacaine|P|ropivacaine|fluvoxamine|In vivo , the plasma clearance of ropivacaine was reduced by 70 % during coadministration of fluvoxamine -LRB- 25 mg bid for 2 days -RRB- , a selective and potent CYP1A2 inhibitor . 
Ropivacaine|P|fluvoxamine|ropivacaine|Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
Ropivacaine|P|ketoconazole|ropivacaine|Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole -LRB- 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole -RRB- caused a 15 % reduction in in-vivo plasma clearance of ropivacaine . 
Rosiglitazone|P|gemfibrozil|rosiglitazone|An inhibitor of CYP2C8 -LRB- such as gemfibrozil -RRB- may increase the AUC of rosiglitazone and an inducer of CYP2C8 -LRB- such as rifampin -RRB- may decrease the AUC of rosiglitazone . 
Rosiglitazone|P|rifampin|rosiglitazone|An inhibitor of CYP2C8 -LRB- such as gemfibrozil -RRB- may increase the AUC of rosiglitazone and an inducer of CYP2C8 -LRB- such as rifampin -RRB- may decrease the AUC of rosiglitazone . 
Roxithromycin|P|macrolide|terfenadine|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|P|macrolide|astemizole|Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
Roxithromycin|P|roxithromycin|terfenadine|Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . 
Roxithromycin|P|roxithromycin|astemizole|Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended . 
Roxithromycin|P|cisapride|macrolide antibacterial|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Roxithromycin|P|pimozide|macrolide antibacterial|- Cisapride , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias -LRB- typically torsades de pointe -RRB- as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
Salmon Calcitonin|P|diphosphonate|calcitonin (salmon)|however , in patients with Paget 's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin -LRB- salmon -RRB- nasal spray . 
Salsalate|P|salicylate drug|disalcid|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|P|aspirin|disalcid|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
Salsalate|P|salicylate|anticoagulant drug|Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding . 
Salsalate|P|salicylate|antidiabetic drug|Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class . 
Salsalate|P|salicylate|triiodothyronine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|phenytoin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|thiopental|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|thyroxine|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|penicillin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|naproxen|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|sulfinpyrazone|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|methotrexate|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|warfarin|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Salsalate|P|salicylate|corticosteroid|Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
Sargramostim|P|leukine|corticosteroid|Drugs which may potentiate the myeloproliferative effects of Leukine , such as lithium and corticosteroids , should be used with caution . 
Sargramostim|P|leukine|corticosteroid|Drugs which may potentiate the myeloproliferative effects of Leukine , such as lithium and corticosteroids , should be used with caution . 
Sargramostim|P|leukine|lithium|Drugs which may potentiate the myeloproliferative effects of Leukine , such as lithium and corticosteroids , should be used with caution . 
Sargramostim|P|leukine|lithium|Drugs which may potentiate the myeloproliferative effects of Leukine , such as lithium and corticosteroids , should be used with caution . 
Scopolamine|P|scopolamine|sedative|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|P|scopolamine|sedative|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|P|scopolamine|alcohol|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|P|scopolamine|alcohol|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|P|scopolamine|tranquilizer|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Scopolamine|P|scopolamine|tranquilizer|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or alcohol . 
Secobarbital|P|barbiturate|corticosteroid|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|P|barbiturate|anticoagulant|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|P|barbiturate|beta blocker|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|P|barbiturate|contraceptive|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|P|barbiturate|antibiotic|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|P|barbiturate|quinidine|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Secobarbital|P|barbiturate|theophylline|Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
Selegiline|P|selegiline|meperidine|The occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine . 
Selegiline|P|meperidine|maoi|This is typical of the interaction of meperidine and MAOIs . 
Selegiline|P|selective serotonin reuptake inhibitor|eldepryl|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL . 
Selegiline|P|tricyclic antidepressant|eldepryl|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL . 
Selegiline|P|selegiline|ephedrine|One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication -LRB- ephedrine-RRB-. 
Selegiline|P|selegiline|sympathomimetic medication|One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication -LRB- ephedrine-RRB-. 
Sitagliptin|P|digoxin|sitagliptin|Digoxin : There was a slight increase in the area under the curve -LRB- AUC , 11 % -RRB- and mean peak drug concentration -LRB- Cmax , 18 % -RRB- of digoxin with the co-administration of 100 mg sitagliptin for 10 days . 
Sodium bicarbonate|P|norepinephrine|sodium bicarbonate|norepinephrine and dobutamine are incompatible with sodium bicarbonate solution . 
Sodium bicarbonate|P|dobutamine|sodium bicarbonate|norepinephrine and dobutamine are incompatible with sodium bicarbonate solution . 
Solifenacin|P|vesicare|ketoconazole|Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors . 
Somatropin recombinant|P|gh|antipyrine|Limited published data indicate that GH treatment increases cytochrome P450 -LRB- CP450 -RRB- mediated antipyrine clearance in man . 
Somatropin recombinant|P|gh|corticosteroid|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|P|gh|cyclosporin|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|P|gh|anticonvulsant|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Somatropin recombinant|P|gh|sex steroid|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes -LRB- e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin -RRB-. 
Sorafenib|P|nexavar|irinotecan|Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway -LRB- e.g. irinotecan -RRB-. 
Sorafenib|P|nexavar|irinotecan|Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway -LRB- e.g. irinotecan -RRB-. 
Sorafenib|P|nexavar|doxorubicin|Concomitant treatment with NEXAVAR resulted in a 21 % increase in the AUC of doxorubicin . 
Sorafenib|P|doxorubicin|nexavar|Caution is recommended when administering doxorubicin with NEXAVAR . 
Stavudine|P|zidovudine|stavudine|Zidovudine competitively inhibits the intracellular phosphorylation of stavudine . 
Stavudine|P|zidovudine|zerit|Therefore , use of zidovudine in combination with ZERIT should be avoided . 
Stavudine|P|stavudine|doxorubicin|In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin . 
Stavudine|P|stavudine|ribavirin|In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin . 
Streptokinase|P|streptase|antiplatelet agent|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|P|streptase|anticoagulant|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|P|streptokinase|antiplatelet agent|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|P|streptokinase|anticoagulant|Use of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
Streptokinase|P|aspirin|streptokinase|The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding -LRB- 3.9 % vs. 3.1 % -RRB- , but does not appear to increase the incidence of major bleeding -LRB- see 
Streptozocin|P|streptozocin|doxorubicin|Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression ; 
Streptozocin|P|doxorubicin|zanosar|a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently . 
Streptozocin|P|streptozocin|phenytoin|The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity . 
Succimer|P|chemet|cana 2 edta|Concomitant administration of CHEMET with other chelation therapy , such as CaNa 2 EDTA is not recommended . 
Sulfamethizole|P|sulfamethizole|barbiturate|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethizole|P|sulfamethizole|tolbutamide|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethizole|P|sulfamethizole|uricosuric|Sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfamethoxazole|P|sulfamethoxazole|warfarin|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin . 
Sulfamethoxazole|P|sulfamethoxazole|warfarin|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin . 
Sulfamethoxazole|P|sulfamethoxazole|phenytoin|Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin . 
Sulfamethoxazole|P|sulfamethoxazole|phenytoin|At a 1.6-g dose , sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate . 
Sulfamethoxazole|P|sulfonamide|methotrexate|Sulfonamides can also displace methotrexate from plasma protein-binding sites , thus increasing free methotrexate concentrations . 
Sulfasalazine|P|digoxin|sulfasalazine|Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine . 
Sulfasalazine|P|folic acid|sulfasalazine|Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine . 
Sulfoxone|P|sulfoxone|barbiturate|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfoxone|P|sulfoxone|tolbutamide|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sulfoxone|P|sulfoxone|uricosuric|Sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics . 
Sumatriptan|P|dihydroergotamine|sumatriptan|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|P|methysergide|sumatriptan|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|P|ergotamine|sumatriptan|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|P|ergot-type medication|sumatriptan|Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications -LRB- like dihydroergotamine or methysergide -RRB- and sumatriptan within 24 hours of each other should be avoided . 
Sumatriptan|P|mao-a inhibitor|sumatriptan|MAO-A inhibitors reduce sumatriptan clearance , significantly increasing systemic exposure . 
Sumatriptan|P|sertraline|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|paroxetine|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|fluvoxamine|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|fluoxetine|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|ssri|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|sumatriptan succinate|mao-a inhibitor|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|selective serotonin reuptake inhibitor|sumatriptan|Therefore , the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors -LRB- SSRIs -RRB- -LRB- e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline -RRB- have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
Sumatriptan|P|sumatriptan|ssri|If concomitant treatment with sumatriptan and an SSRI is clinically warranted , appropriate observation of the patient is advised . 
Sunitinib|P|sutent|clarithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|voriconizole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|itraconazole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|ketoconazole|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|nelfinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|nefazodone|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|indinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|atazanavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|telithromycin|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|ritonavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|saquinavir|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family -LRB- e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole -RRB- may increases sunitinib concentrations . 
Sunitinib|P|sutent|dexamethasone|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|P|sutent|phenobarbital|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|P|sutent|rifapentin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|P|sutent|carbamazepine|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|P|sutent|phenytoin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|P|sutent|rifabutin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Sunitinib|P|sutent|rifampin|Co-administration of SUTENT with inducers of the CYP3A4 family -LRB- e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort -RRB- may decrease sunitinib concentrations . 
Suprofen|P|carbachol|suprofen|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|P|isopto carbachol|suprofen|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|P|carboptic|suprofen|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|P|miochol|suprofen|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Suprofen|P|acetylcholine chloride|suprofen|Other eye drops or medications such as acetylcholine chloride -LRB- Miochol -RRB- and carbachol -LRB- Carboptic , Isopto Carbachol -RRB- may decrease the effects of suprofen ophthalmic . 
Tamsulosin|P|flomax|alpha-adrenergic blocking agent|However , interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents . 
Tamsulosin|P|flomax|cimetidine|Therefore , FLOMAX capsules should be used with caution in combination with cimetidine , particularly at doses higher than 0.4 mg . 
Tamsulosin|P|warfarin|flomax|Therefore , caution should be exercised with concomitant administration of warfarin and FLOMAX capsules . 
Temozolomide|P|valproic acid|temozolomide|Administration of valproic acid decreases oral clearance of temozolomide by about 5 %. 
Tenecteplase|P|anticoagulant|tnkase|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|P|dipyridamole|tnkase|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|P|acetylsalicylic acid|tnkase|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|P|heparin|tnkase|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Tenecteplase|P|vitamin k antagonist|tnkase|Anticoagulants -LRB- such as heparin and vitamin K antagonists -RRB- and drugs that alter platelet function -LRB- such as acetylsalicylic acid , dipyridamole , and GP IIb/IIIa inhibitors -RRB- may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
Teniposide|P|tolbutamide|teniposide|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|P|sulfamethizole|teniposide|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|P|sodium salicylate|teniposide|In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent . 
Teniposide|P|methotrexate|teniposide|An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide . 
Terbinafine|P|terbinafine|caffeine|Terbinafine decreases the clearance of caffeine by 19 %. 
Terbinafine|P|terbinafine|cyclosporine|Terbinafine increases the clearance of cyclosporine by 15 %. 
Terbinafine|P|terbinafine|warfarin|There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between LAMISIL Tablets and these changes has not been established . 
Terbinafine|P|terbinafine|rifampin|Terbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . 
Terbinafine|P|terbinafine|cimetidine|Terbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . 
Terfenadine|P|ketoconazole|terfenadine|Ketoconazole : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events , e.g. . 
Terfenadine|P|ketoconazole|terfenadine|Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine , resulting in elevated plasma terfenadine levels . 
Terfenadine|P|ketoconazole|terfenadine|Concomitant administration of ketoconazole and terfenadine is contraindicated . 
Terfenadine|P|terfenadine|itraconazole|Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources . 
Terfenadine|P|itraconazole|terfenadine|Concomitant administration of itraconazole and terfenadine is contraindicated . 
Terfenadine|P|miconazole|terfenadine|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|P|metronidazole|terfenadine|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|P|fluconazole|terfenadine|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|P|azole-type antifungal agent|terfenadine|Due to the chemical similarity of other azole-type antifungal agents -LRB- including fluconazole , metronidazole , and miconazole -RRB- to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
Terfenadine|P|erythromycin|terfenadine|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|P|clarithromycin|terfenadine|Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
Terfenadine|P|terfenadine|azithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|P|terfenadine|troleandomycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|P|terfenadine|erythromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|P|terfenadine|clarithromycin|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Terfenadine|P|terfenadine|macrolide antibiotic|Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
Testolactone|P|testolactone|anticoagulant|When administered concurrently , testolactone may increase the effects of oral anticoagulants ; 
Thalidomide|P|thalidomide|barbiturate|Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . 
Thalidomide|P|john's wort|hormonal contraceptive agent|John 's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies . 
Thiabendazole|P|thiabendazole|theophylline|Thiabendazole may compete with other drugs , such as theophylline , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels . 
Thiabendazole|P|thiabendazole|xanthine derivative|Therefore , when concomitant use of thiabendazole and xanthine derivatives is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds . 
Thiamine|P|thiamine|tricyclic antidepressant|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|thiamine|stavudine|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|thiamine|contraceptive|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|thiamine|loop diuretic|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|vitamin b1|tricyclic antidepressant|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|vitamin b1|stavudine|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|vitamin b1|contraceptive|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiamine|P|vitamin b1|loop diuretic|Interactions for Vitamin B1 -LRB- Thiamine -RRB- : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
Thiethylperazine|P|phenothiazine|anesthetic|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|P|phenothiazine|barbiturate|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|P|phenothiazine|alcohol|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|P|phenothiazine|opiate|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thiethylperazine|P|phenothiazine|cns depressant|Phenothiazines are capable of potentiating CNS depressants -LRB- e.g. , barbiturates , anesthetics , opiates , alcohol , etc .-RRB- 
Thioguanine|P|mercaptopurine|thioguanine|There is usually complete cross-resistance between PURINETHOL -LRB- mercaptopurine -RRB- and TABLOID brand Thioguanine . 
Thioguanine|P|mercaptopurine|tabloid|There is usually complete cross-resistance between PURINETHOL -LRB- mercaptopurine -RRB- and TABLOID brand Thioguanine . 
Thioguanine|P|purinethol|thioguanine|There is usually complete cross-resistance between PURINETHOL -LRB- mercaptopurine -RRB- and TABLOID brand Thioguanine . 
Thioguanine|P|purinethol|tabloid|There is usually complete cross-resistance between PURINETHOL -LRB- mercaptopurine -RRB- and TABLOID brand Thioguanine . 
Thioguanine|P|aminosalicylate derivative|thioguanine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|P|sulphasalazine|thioguanine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|P|olsalazine|thioguanine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thioguanine|P|mesalazine|thioguanine|As there is in vitro evidence that aminosalicylate derivatives -LRB- e.g. , olsalazine , mesalazine , or sulphasalazine -RRB- inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
Thymalfasin|P|zadaxin|immunomodulating drug|Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs . 
Tigecycline|P|tigecycline|warfarin|Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin . 
Tigecycline|P|antibacterial drug|contraceptive|Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective . 
Tiludronate|P|skelid|calcium|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|P|aluminum|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|P|magnesium|skelid|The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before SKELID . 
Tiludronate|P|aspirin|skelid|Aspirin may decrease bioavailability of SKELID by up to 50 % when taken 2 hours after SKELID . 
Tiludronate|P|skelid|indomethacin|The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac . 
Tiotropium|P|spiriva|anticholinergic|However , the co administration of SPIRIVA with other anticholinergic containing drugs -LRB- e.g. , ipratropium -RRB- has not been studied and is therefore not recommended . 
Tiotropium|P|spiriva|ipratropium|However , the co administration of SPIRIVA with other anticholinergic containing drugs -LRB- e.g. , ipratropium -RRB- has not been studied and is therefore not recommended . 
Tirofiban|P|aggrastat|heparin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tirofiban|P|aggrastat|aspirin|The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone -LRB- see 
Tobramycin|P|tobi|anti-pseudomonal antibiotic|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|P|tobi|corticosteroid|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|P|tobi|aminoglycoside|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|P|tobi|(beta)-agonist|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|P|tobi|dornase alfa|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|P|tobi|pulmozyme|In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa -LRB- PULMOZYME , Genentech -RRB- , -LRB- beta -RRB- -agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
Tobramycin|P|diuretic|aminoglycoside|Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue . 
Tobramycin|P|tobi|urea|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|P|tobi|mannitol|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|P|tobi|ethacrynic acid|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tobramycin|P|tobi|furosemide|TOBI should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol . 
Tolmetin|P|tolectin|warfarin|However , increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy . 
Tolmetin|P|tolectin|anticoagulant|Therefore , caution should be exercised when administering TOLECTIN to patients on anticoagulants . 
Tolmetin|P|tolectin|methotrexate|Caution should be used if TOLECTIN is administered concomitantly with methotrexate . 
Tolmetin|P|nonsteroidal anti-inflammatory drug|methotrexate|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
Tolmetin|P|tolectin|methotrexate|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
Tolterodine|P|ketoconazole|tolterodine|CYP3A4 Inhibitors : Ketoconazole , an inhibitor of the drug metabolizing enzyme CYP3A4 , significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers -LRB- see CLINICAL PHARMACOLOGY , Variability in Metabolism and Drug-Drug Interactions -RRB-. 
Tolterodine|P|macrolide antibiotic|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|erythromycin|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|azole antifungal|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|clarithromycin|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|itraconazole|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|cyclosporine|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|vinblastine|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|vinblastine|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|ketoconazole|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Tolterodine|P|miconazole|detrol la|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals -LRB- eg , itraconazole , miconazole -RRB- or macrolide antibiotics -LRB- eg , erythromycin , clarithromycin -RRB- or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
Trastuzumab|P|paclitaxel|herceptin|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . 
Trilostane|P|trilostane|mitotane|Trilostane may interact with aminoglutethimide or mitotane -LRB- causing too great a decrease in adrenal function -RRB-. 
Trilostane|P|trilostane|aminoglutethimide|Trilostane may interact with aminoglutethimide or mitotane -LRB- causing too great a decrease in adrenal function -RRB-. 
Trimethoprim|P|trimethoprim|phenytoin|Trimethoprim may inhibit the hepatic metabolism of phenytoin . 
Trimethoprim|P|trimethoprim|phenytoin|Trimethoprim , given at a common clinical dosage , increased the phenytoin half-life by 51 % and decreased the phenytoin metabolic clearance rate by 30 %. 
Trimethoprim|P|trimethoprim|phenytoin|Trimethoprim , given at a common clinical dosage , increased the phenytoin half-life by 51 % and decreased the phenytoin metabolic clearance rate by 30 %. 
Trimetrexate|P|trimetrexate|erythromycin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|erythromycin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|rifabutin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|rifabutin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|rifampin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|rifampin|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|fluconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|trimetrexate|ketoconazole|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole . 
Trimetrexate|P|cimetidine|trimetrexate|In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 
Trimetrexate|P|ketoconazole|trimetrexate|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|P|miconazole|trimetrexate|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|P|imidazole drug|trimetrexate|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Trimetrexate|P|clotrimazole|trimetrexate|Based on an in vitro rat liver model , nitrogen substituted imidazole drugs -LRB- clotrimazole , ketoconazole , miconazole -RRB- were potent , non-competitive inhibitors of trimetrexate metabolism . 
Triprolidine|P|triprolidine|narcotic analgesic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|triprolidine|hypnotic|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|triprolidine|barbiturate|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|triprolidine|alcohol|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|triprolidine|tranquilliser|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|triprolidine|sedative|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|triprolidine|central nervous system depressant|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
Triprolidine|P|tricyclic antidepressant|triprolidine|The effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
Triprolidine|P|atropine|triprolidine|The effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
Triprolidine|P|anticholinergic drug|triprolidine|The effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
Trospium|P|sanctura|anticholinergic agent|The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects . 
Trospium|P|sanctura|pancuronium|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|P|sanctura|tenofovir|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|P|sanctura|metformin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|P|sanctura|vancomycin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|P|sanctura|morphine|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|P|sanctura|procainamide|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Trospium|P|sanctura|digoxin|Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug-drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion -LRB- e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir -RRB-. 
Vancomycin|P|vancomycin|anesthetic agent|Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions . 
Vigabatrin|P|vigabatrin|carbamazepine|A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine . 
Vigabatrin|P|vigabatrin|phenytoin|In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy . 
Vindesine|P|vindesine|live virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|P|vindesine|phenytoin|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|P|vindesine|mitomycin-c|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vindesine|P|vindesine|killed virus vaccine|Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose-related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin-C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
Vitamin A|P|contraceptive|vitamin a|Drug Interactions : Women on oral contraceptives have shown a significant increase in plasma vitamin A levels . 
Vitamin C|P|ascorbic acid|bishydroxycoumarin|Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin . 
Vorinostat|P|zolinza|coumarin-derivative anticoagulant|Coumarin-Derivative Anticoagulants : Prolongation of prothrombin time -LRB- PT -RRB- and International Normalized Ratio -LRB- INR -RRB- were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants . 
Vorinostat|P|zolinza|coumarin derivative|Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives . 
Vorinostat|P|zolinza|valproic acid|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors -LRB- e.g. , valproic acid -RRB-. 
Vorinostat|P|zolinza|hdac inhibitor|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors -LRB- e.g. , valproic acid -RRB-. 
